SOX17 and pulmonary arterial hypertension: Shortly after Graf et al.'s work, Zhu et al., demonstrated an enrichment of rare deleterious SOX17 mutations in patients with PAH associated with congenital heart disease (PAH-CHD) (3.2% of patients) and in patients with IPAH/HPAH (0.7% of patients).